NCT06613217View on ClinicalTrials.gov

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2026

Conditions
Relapsed Adult AML
Interventions
DRUG

zelenirstat

Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Centre, Houston

Sponsors

Collaborators (1)

Ozmosis Research Inc.
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Pacylex Pharmaceuticals

INDUSTRY